| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Division of Cardiac Surgery, Toronto General Research Institute, University of Toronto, Toronto General Hospital, Toronto M5G 2C4; and 2 Roy and Ann Foss Interventional Cardiology Research Program, Division of Cardiology, Terrence Donnelly Heart Centre, University of Toronto, St. Michael's Hospital, Toronto, Ontario, Canada M5B 1W8
In the failing heart, an imbalance in
matrix metalloproteinases (MMPs) and their biological regulators, the
tissue inhibitors of MMPs (TIMPs), may result in cardiac dilatation
from matrix degradation. We hypothesized that a reduction of myocardial
TIMP-3 is associated with adverse matrix remodeling in both human and experimental heart failure. Cardiomyopathic hamsters at age 15 wk
(normal), 25 wk (compensated stage), and 35 wk (overt failure) were
compared with age-matched normal controls. MMP activity (gelatinase bioassay) was increased in cardiomyopathic hearts (P = 0.03) and peaked during the transition to overt heart failure. TIMP-3
content (immunoblot) was decreased compared with normal controls
(74 ± 5% at 25 wk, 69 ± 10% at 35 wk; P = 0.001) and its reduction was associated with increased MMP activity
(r = 
0.6; P = 0.004). TIMP-1
increased progressively (P = 0.001), whereas TIMP-2,
TIMP-4, and MMP protein levels were unchanged. Myocardial collagen
(hydroxyproline content) increased with time during the progression to
end-stage cardiac failure (P < 0.0001). Collagen
synthesis ([14C]proline uptake) was elevated in
cardiomyopathy at 15 and 25 wk (P < 0.05). The
collagen cross-linking ratio (insoluble:soluble collagen) was reduced
(P = 0.003) as the left ventricle dilated. By confocal
microscopy restricted to viable myocardium, collagen content was
reduced (P = 0.04) with fragmentation
(P < 0.0001) and thinning (P = 0.003)
of perimysial collagen fibers. Similarly, patients with end-stage
congestive heart failure (n = 7) compared with
nonfailing controls (n = 2) had elevated gelatinase MMP
activity (P = 0.02) associated with isolated reductions
in TIMP-3 (55 ± 5% of normal; P = 0.003).
Reductions of TIMP-3 parallel adverse matrix remodeling in the
cardiomyopathic hamster and the failing human heart. TIMP-3 may
contribute to the regulation of myocardial remodeling and its reduction
may promote a transition from compensated to end-stage congestive heart failure.
tissue inhibitor of matrix metalloproteinases
This article has been cited by other articles:
|
|
 |
|
  L. Hammoud, D. E. Burger, X. Lu, and Q. Feng Tissue inhibitor of metalloproteinase-3 inhibits neonatal mouse cardiomyocyte proliferation via EGFR/JNK/SP-1 signaling Am J Physiol Cell Physiol, April 1, 2009; 296(4): C735 - C745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Angoulvant, S. Fazel, R. D. Weisel, T. Y.Y. Lai, P. W. Fedak, L. Chen, S. Rafati, C. K. Seneviratne, N. Degousee, and R.-K. Li Cell-based gene therapy modifies matrix remodeling after a myocardial infarction in tissue inhibitor of matrix metalloproteinase-3-deficient mice. J. Thorac. Cardiovasc. Surg., February 1, 2009; 137(2): 471 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Farahmand, T. Y.Y. Lai, R. D. Weisel, S. Fazel, T. Yau, P. Menasche, and R.-K. Li Skeletal Myoblasts Preserve Remote Matrix Architecture and Global Function When Implanted Early or Late After Coronary Ligation Into Infarcted or Remote Myocardium Circulation, September 30, 2008; 118(14_suppl_1): S130 - S137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Gallegos and R. M. Bolman III Stem Cell Induced Regeneration of Myocardium Card. Surg. Adult, January 1, 2008; 3(2008): 1657 - 1668. [Full Text]
|
|
|
|
 |
|
 H. Aupperle, J. Garbade, A. Schubert, M. Barten, S. Dhein, H.-A Schoon, and F.-W Mohr Effects of Autologous Stem Cells on Immunohistochemical Patterns and Gene Expression of Metalloproteinases and Their Tissue Inhibitors in Doxorubicin Cardiomyopathy in a Rabbit Model Vet. Pathol., July 1, 2007; 44(4): 494 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Graham and A. W. Trafford Spatial disruption and enhanced degradation of collagen with the transition from compensated ventricular hypertrophy to symptomatic congestive heart failure Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1364 - H1372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Trescher, O. Bernecker, B. Fellner, M. Gyongyosi, R. Schafer, S. Aharinejad, R. DeMartin, E. Wolner, and B. K. Podesser Inflammation and postinfarct remodeling: Overexpression of I{kappa}B prevents ventricular dilation via increasing TIMP levels Cardiovasc Res, February 15, 2006; 69(3): 746 - 754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Yau, C. Kim, D. Ng, G. Li, Y. Zhang, R. D. Weisel, and R.-K. Li Increasing Transplanted Cell Survival With Cell-Based Angiogenic Gene Therapy Ann. Thorac. Surg., November 1, 2005; 80(5): 1779 - 1786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W.M. Fedak, P. E. Szmitko, R. D. Weisel, S. M. Altamentova, N. Nili, N. Ohno, S. Verma, S. Fazel, B. H. Strauss, and R.-K. Li Cell transplantation preserves matrix homeostasis: A novel paracrine mechanism J. Thorac. Cardiovasc. Surg., November 1, 2005; 130(5): 1430 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mizuno, R. D. Weisel, and R.-K. Li Reloading the heart: A new animal model of left ventricular assist device removal J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 99 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Yau, G. Li, Y. Zhang, R. D. Weisel, D. A.G. Mickle, and R.-K. Li Vascular Endothelial Growth Factor Receptor Upregulation in Response to Cell-Based Angiogenic Gene Therapy Ann. Thorac. Surg., June 1, 2005; 79(6): 2056 - 2063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fazel, G. H.L. Tang, D. Angoulvant, M. Cimini, R. D. Weisel, R.-K. Li, and T. M. Yau Current Status of Cellular Therapy for Ischemic Heart Disease Ann. Thorac. Surg., June 1, 2005; 79(6): S2238 - S2247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Lovelock, A. H. Baker, F. Gao, J.-F. Dong, A. L. Bergeron, W. McPheat, N. Sivasubramanian, and D. L. Mann Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H461 - H468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Jayasankar, Y. J. Woo, L. T. Bish, T. J. Pirolli, M. F. Berry, J. Burdick, R. C. Bhalla, R. V. Sharma, T. J. Gardner, and H. L. Sweeney Inhibition of Matrix Metalloproteinase Activity by TIMP-1 Gene Transfer Effectively Treats Ischemic Cardiomyopathy Circulation, September 14, 2004; 110(11_suppl_1): II-180 - II-186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Stawowy, C. Margeta, H. Kallisch, N. G Seidah, M. Chretien, E. Fleck, and K. Graf Regulation of matrix metalloproteinase MT1-MMP/MMP-2 in cardiac fibroblasts by TGF-{beta}1 involves furin-convertase Cardiovasc Res, July 1, 2004; 63(1): 87 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Gong, A. Rifai, E. M. Tolbert, J. N. Centracchio, and L. D. Dworkin Hepatocyte Growth Factor Modulates Matrix Metalloproteinases and Plasminogen Activator/Plasmin Proteolytic Pathways in Progressive Renal Interstitial Fibrosis J. Am. Soc. Nephrol., December 1, 2003; 14(12): 3047 - 3060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Chen, D. Li, T. Saldeen, and J. L. Mehta TGF-beta 1 attenuates myocardial ischemia-reperfusion injury via inhibition of upregulation of MMP-1 Am J Physiol Heart Circ Physiol, May 1, 2003; 284(5): H1612 - H1617. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
